Factors affecting transmission of mucosal human papillomavirus

The Lancet Infectious Diseases

Volumn 10, Issue 12, 2010, Pages 862-874

  Veldhuijzen, Nienke J ^a   Snijders, Peter JF ^b   Reiss, Peter ^a   Meijer, Chris JLM ^b   van de Wijgert, Janneke HHM ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL THERAPY; CIRCUMCISION; CONDOM; HOST; HUMAN; INFECTION SENSITIVITY; MUCOSAL IMMUNITY; PERSISTENT VIRUS INFECTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SEXUALLY TRANSMITTED DISEASE; VACCINATION; VIRUS INFECTIVITY; VIRUS TRANSMISSION; WART VIRUS;

DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HUMANS; MALE; MUCOUS MEMBRANE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES, VIRAL;

EID: 78649445000     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70190-0     Document Type: Review

References (149)

1. Aral SO, Holmes KK The epidemiology of STIs and their social and behavioral determinants: industrialized and developing countries. Sexually transmitted diseases 2008, 72-73. McGraw-Hill, New York. 4th edn. K.K. Holmes, P.F. Sparling, W.E. Stamm (Eds.).
2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H Classification of papillomaviruses. Virology 2004, 324:17-27.
3. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
4. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008, 26(suppl 10):K17-K28.
5. Heideman DA, Waterboer T, Pawlita M, et al. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 2007, 25:4550-4556.
6. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10 Lyon, France: International Agency for Research on Cancer (accessed April 30, 2010). http://globocan.iarc.fr.
7. Doorbar J The papillomavirus life cycle. J Clin Virol 2005, 32(suppl 1):S7-S15.
8. Moscicki AB Impact of HPV infection in adolescent populations. J Adolesc Health 2005, 37(6 suppl):S3-S9.
9. Stanley M Immune responses to human papillomavirus. Vaccine 2006, 24(suppl 1):S16-S22.
10. Fehrmann F, Laimins LA Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 2003, 22:5201-5207.
11. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009, 9:347-356.
12. Frazer I Correlating immunity with protection for HPV infection. Int J Infect Dis 2007, 11(suppl 2):S10-S16.
13. Bulkmans NW, Berkhof J, Bulk S, et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007, 96:1419-1424.
14. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181:1911-1919.
15. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009, 200:1059-1067.
16. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004, 13:324-327.
17. Viscidi RP, Snyder B, Cu-Uvin S, et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 2005, 14:283-288.
18. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007, 25:4931-4939.
19. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years. Lancet 2009, 374:1975-1985. on behalf of the HPV Vaccine Study group.
20. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255. on behalf of the HPV vaccine study group.
21. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.
22. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
23. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Phila) 2009, 2:868-878.
24. Ault KA Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369:1861-1868.
25. Syrjanen K, Hakama M, Saarikoski S, et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis 1990, 17:15-19.
26. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(suppl 10):K1-K16.
27. Smith JS, Melendy A, Rana RK, Pimenta JM Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008, 43(4 suppl):S5-S25. S25 e1-41.
28. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7:453-459.
29. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366:991-998.
30. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006, 119:2677-2684.
31. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008, 17:2036-2043.
32. Ogilvie GS, Taylor DL, Achen M, Cook D, Krajden M Self-collection of genital human papillomavirus specimens in heterosexual men. Sex Transm Infect 2009, 85:221-225.
33. Bosch FX, Castellsague X, Muñoz N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996, 88:1060-1067.
34. Burchell AN, Tellier PP, Hanley J, Coutlee F, Franco EL Human Papillomavirus infections among couples in new sexual relationships. Epidemiology 2010, 21:31-37.
35. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010, 102:315-324.
36. Goodman MT, Shvetsov YB, McDuffie K, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008, 68:8813-8824.
37. Safaeian M, Kiddugavu M, Gravitt PE, et al. Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev 2008, 17:1300-1307.
38. Dev D, Lo Y, Ho GY, Burk RD, Klein RS Incidence of and risk factors for genital human papillomavirus infection in women drug users. J Acquir Immune Defic Syndr 2006, 41:527-529.
39. Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001, 184:682-690.
40. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003, 12:485-490.
41. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004, 190:2077-2087.
42. Fukuchi E, Sawaya GF, Chirenje M, et al. Cervical human papilloma virus incidence and persistence in a cohort of HIV-negative women in Zimbabwe. Sex Transm Dis 2009, 36:305-311.
43. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008, 197:279-282.
44. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428.
45. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002, 186:737-742.
46. Rousseau MC, Abrahamowicz M, Villa LL, Costa MC, Rohan TE, Franco EL Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2003, 12:1029-1037.
47. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001, 285:2995-3002.
48. Kjaer SK, Chackerian B, van den Brule AJ, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001, 10:101-106.
49. Nielsen A, Iftner T, Munk C, Kjaer SK Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women. Sex Transm Dis 2009, 36:609-615.
50. Chao A, Chang CJ, Lai CH, et al. Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology-a population-based cohort study from Taiwan. Int J Cancer 2010, 126:191-198.
51. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157:218-226.
52. Morrison CS, Turner AN, Jones LB Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol 2009, 23:263-284.
53. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999, 341:1432-1438.
54. McClelland RS, Lavreys L, Katingima C, et al. Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis 2005, 191:333-338.
55. Braunstein SL, van de Wijgert JH, Nash D HIV incidence in sub-Saharan Africa: a review of available data with implications for surveillance and prevention planning. AIDS Rev 2009, 11:140-156.
56. Lajous M, Mueller N, Cruz-Valdez A, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005, 14:1710-1716.
57. Kjaer SK, Munk C, Winther JF, Jorgensen HO, Meijer CJ, van den Brule AJ Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005, 14:1528-1533.
58. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007, 196:1128-1136.
59. Lu B, Wu Y, Nielson CM, et al. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis 2009, 199:362-371.
60. Hernandez BY, Wilkens LR, Zhu X, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008, 14:888-894.
61. Burchell AN, Winer RL, de Sanjose S, Franco EL Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006, 24:S3. 52-61.
62. Bleeker MC, Hogewoning CJ, Voorhorst FJ, et al. HPV-associated flat penile lesions in men of a non-STD hospital population: less frequent and smaller in size than in male sexual partners of women with CIN. Int J Cancer 2005, 113:36-41.
63. Bleeker MC, Hogewoning CJ, Berkhof J, et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 2005, 41:612-620.
64. Burchell AN, Richardson H, Mahmud SM, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 2006, 163:534-543.
65. Burchell AN, Hanley J, Tellier PP, Coutlee F, Franco EL. Probability of HPV transmission among newly-formed couples. International Papillomavirus Conference 2009; Malmö, Sweden; May 8-14, 2009.
66. Sinal SH, Woods CR Human papillomavirus infections of the genital and respiratory tracts in young children. Semin Pediatr Infect Dis 2005, 16:306-316.
67. Rintala MA, Grenman SE, Puranen MH, et al. Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland. J Clin Microbiol 2005, 43:376-381.
68. Dunne EF, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 in children. J Infect Dis 2005, 191:1817-1819.
69. Rice PS, Cason J, Best JM, Banatvala JE High risk genital papillomavirus infections are spread vertically. Rev Med Virol 1999, 9:15-21.
70. Mammas IN, Sourvinos G, Spandidos DA Human papilloma virus (HPV) infection in children and adolescents. Eur J Pediatr 2009, 168:267-273.
71. Doerfler D, Bernhaus A, Kottmel A, Sam C, Koelle D, Joura EA Human papilloma virus infection prior to coitarche. Am J Obstet Gynecol 2009, 200:487. e1-5.
72. Syrjanen S, Puranen M Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med 2000, 11:259-274.
73. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006, 354:2645-2654.
74. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006, 194:1044-1057.
75. Fenton KA, Johnson AM, McManus S, Erens B Measuring sexual behaviour: methodological challenges in survey research. Sex Transm Infect 2001, 77:84-92.
76. Peterman TA, Lin LS, Newman DR, et al. Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Sex Transm Dis 2000, 27:446-451. for the Project RESPECT Study Group.
77. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003, 107:811-816.
78. Bleeker MC, Berkhof J, Hogewoning CJ, et al. HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. Br J Cancer 2005, 92:1388-1392.
79. Castle PE, Jeronimo J, Schiffman M, et al. Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res 2006, 66:1218-1224.
80. Hildesheim A, Wang SS Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002, 89:229-240.
81. de Araujo Souza PcS, Sichero L, Maciag PC HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer. Future Oncol 2009, 5:359-370.
82. Segat L, Crovella S, Comar M, et al. MBL2 gene polymorphisms are correlated with high-risk human papillomavirus infection but not with human papillomavirus-related cervical cancer. Hum Immunol 2009, 70:436-439.
83. Parrella P, Seripa D, Matera MG, et al. Lack of association between genetic variants in the mannose-binding lectin 2 (MBL2) gene and HPV infection. Eur J Epidemiol 2007, 22:159-162.
84. Veroux M, Corona D, Scalia G, et al. Surveillance of human papilloma virus infection and cervical cancer in kidney transplant recipients: preliminary data. Transplant Proc 2009, 41:1191-1194.
85. Ozsaran AA, Ates T, Dikmen Y, et al. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur J Gynaecol Oncol 1999, 20:127-130.
86. De Vuyst H, Lillo F, Broutet N, Smith JS HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008, 17:545-554.
87. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997, 337:1343-1349.
88. Minkoff H, Feldman J, DeHovitz J, Landesman S, Burk R A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 1998, 178:982-986.
89. Silverberg MJ, Ahdieh L, Munoz A, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002, 29:427-435.
90. Branca M, Garbuglia AR, Benedetto A, et al. Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up. Int J STD AIDS 2003, 14:417-425.
91. Moscicki AB, Ellenberg JH, Farhat S, Xu J Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004, 190:37-45.
92. Watts DH, Fazzari M, Minkoff H, et al. Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis 2005, 191:1129-1139.
93. Koshiol JE, Schroeder JC, Jamieson DJ, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006, 119:1623-1629.
94. Rowhani-Rahbar A, Hawes SE, Sow PS, et al. The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis 2007, 196:887-894.
95. Fontaine J, Hankins C, Money D, et al. Human papillomavirus type 16 (HPV-16) viral load and persistence of HPV-16 infection in women infected or at risk for HIV. J Clin Virol 2008, 43:307-312.
96. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005, 97:577-586.
97. Clifford GM, Goncalves MA, Franceschi S Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006, 20:2337-2344.
98. Ng'ayo MO, Bukusi E, Rowhani-Rahbar A, et al. Epidemiology of human papillomavirus infection among fishermen along Lake Victoria Shore in the Kisumu District, Kenya. Sex Transm Infect 2008, 84:62-66.
99. Fife KH, Wu JW, Squires KE, Watts DH, Andersen JW, Brown DR Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 51:274-282.
100. Palefsky J Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS 2009, 4:52-56.
101. Paramsothy P, Jamieson DJ, Heilig CM, et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009, 113:26-31.
102. Ahdieh-Grant L, Li R, Levine AM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004, 96:1070-1076.
103. Moore AL, Sabin CA, Madge S, Mocroft A, Reid W, Johnson MA Highly active antiretroviral therapy and cervical intraepithelial neoplasia. Aids 2002, 16:927-929.
104. Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001, 184:547-551.
105. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009, 199:14-19.
106. Smith-Mccune K, Chirenje Z, Magure T et al. Detection of type-specific cervicovaginal human papillomavirus increases risk of HIV infetion independent of other sexually transmitted infections. Conference on Retroviruses and Opportunistic Infections 2009; Montreal, Canada; Feb 8-11, 2009.
107. Smith JS, Moses S, Hudgens MG, et al. Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dis 2010, 201:1677-1685.
108. Averbach SH, Gravitt PE, Nowak RG, et al. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS 2010, 24:1035-1042.
109. Smith JS, Green J, de Gonzalez A Berrington, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003, 361:1159-1167.
110. Green J, de Gonzalez A Berrington, Smith JS, et al. Human papillomavirus infection and use of oral contraceptives. Br J Cancer 2003, 88:1713-1720.
111. Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance and predictors of human papillomavirus infection in women. Cmaj 2003, 168:421-425.
112. Giuliano AR, Papenfuss MR, Denman CA, de Zapien JG, Abrahamsen M, Hunter JB Human papillomavirus prevalence at the USA-Mexico border among women 40 years of age and older. Int J STD AIDS 2005, 16:247-251.
113. del Amo J, Gonzalez C, Losana J, et al. Influence of age and geographical origin in the prevalence of high risk human papillomavirus in migrant female sex workers in Spain. Sex Transm Infect 2005, 81:79-84.
114. Rousseau MC, Franco EL, Villa LL, et al. A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 2000, 9:469-476.
115. Castellsague X, Muñoz N Chapter 3: Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003, 31:20-28.
116. Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 2003, 14:805-814.
117. Minkoff H, Feldman JG, Strickler HD, et al. Relationship between smoking and human papillomavirus infections in HIV-infected and -uninfected women. J Infect Dis 2004, 189:1821-1828.
118. Sopori M Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002, 2:372-377.
119. Verhoeven V, Baay M, Weyler J, et al. Concomitant Chlamydia trachomatis and human papilloma virus infection cannot be attributed solely to sexual behaviour. Eur J Clin Microbiol Infect Dis 2004, 23:735-737.
120. Samoff E, Koumans EH, Markowitz LE, et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005, 162:668-675.
121. Finan RR, Musharrafieh U, Almawi WY Detection of Chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. Clin Microbiol Infect 2006, 12:927-930.
122. Silins I, Ryd W, Strand A, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005, 116:110-115.
123. Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002, 346:1105-1112.
124. Allsworth JE, Lewis VA, Peipert JF Viral sexually transmitted infections and bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Sex Transm Dis 2008, 35:791-796.
125. Lippman SA, Sucupira MC, Jones HE, et al. Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women. Int J STD AIDS 2010, 21:105-109.
126. da Silva CS, Adad SJ, de Souza MA Hazarabedian, Barcelos AC Macedo, Terra AP Sarreta, Murta EF Increased frequency of bacterial vaginosis and Chlamydia trachomatis in pregnant women with human papillomavirus infection. Gynecol Obstet Invest 2004, 58:189-193.
127. Nam KH, Kim YT, Kim SR, et al. Association between bacterial vaginosis and cervical intraepithelial neoplasia. J Gynecol Oncol 2009, 20:39-43.
128. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009, 360:1298-1309.
129. Van Howe RS Human papillomavirus and circumcision: a meta-analysis. J Infect 2007, 54:490-496.
130. Shvetsov Y, Wilkens L, Goodman M, et al. Circumcision status affects genital human papillomavirus infection in men. International Papillomavirus Conference 2009, Malmö, Sweden; May 8-14, 2009.
131. Serwadda D, Wawer MJ, Makumbi F, et al. Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda. J Infect Dis 2010, 201:1463-1469.
132. Gray RH, Serwadda D, Kong X, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 2010, 201:1455-1462.
133. Baeten JM, Donnell D, Kapiga SH, et al. Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples. AIDS 2010, 24:737-744.
134. Castellsague X, Peeling RW, Franceschi S, et al. Chlamydia trachomatis infection in female partners of circumcised and uncircumcised adult men. Am J Epidemiol 2005, 162:907-916.
135. Turner AN, Morrison CS, Padian NS, et al. Male circumcision and women's risk of incident chlamydial, gonococcal, and trichomonal infections. Sex Transm Dis 2008, 35:689-695.
136. Zenilman JM, Fresia A, Berger B, McCormack WM Bacterial vaginosis is not associated with circumcision status of the current male partner. Sex Transm Infect 1999, 75:347-348.
137. Weissenborn SJ, Funke AM, Hellmich M, et al. Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated. J Clin Microbiol 2003, 41:2763-2767.
138. Winer RL, Harris TG, Xi LF, et al. Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol 2009, 81:713-721.
139. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168:123-137.
140. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999, 180:1415-1423.
141. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis 2002, 186:462-469.
142. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005, 191:182-192.
143. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003, 158:486-494.
144. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001, 357:1831-1836.
145. Trottier H, Mahmud S, Prado JC, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008, 197:1436-1447.
146. Rowhani-Rahbar A, Hughes JP, Koutsky LA Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection. Sex Transm Dis 2009, 36:261-263.
147. Fichorova RN, Richardson-Harman N, Alfano M, et al. Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 2008, 80:4741-4751.
148. Jespers V, Harandi AM, Hinkula J, et al. Assessment of mucosal immunity to HIV-1. Expert Rev Vaccines; 9: 381-94.
149. Chow LT, Duffy AA, Wang HK, Broker TR A highly efficient system to produce infectious human papillomavirus: Elucidation of natural virus-host interactions. Cell Cycle 2009, 8:1319-1323.